|PD-L1 Inhibitor Avelumab May Improve Survival in Metastatic Urothelial Carcinoma|
Urothelial carcinoma, the most common subtype of bladder cancer, presents a host of treatment challenges, says Andrea B. Apolo, MD, a medical oncologist at the National Cancer Institute (NCI) and chief of the Bladder Sancer Section of the NCI's ...
OncLive - Wed, 07 Oct 2015 06:18
|Avelumab Receives Fast-Track for Merkel Cell Carcinoma|
A new PD-L1 inhibitor being developed by Pfizer and Merck has been placed on the Fast Track by the FDA. Avelumab is a fully humanized anti-PD-L1 monoclonal antibody being developed for metastatic Merkel cell carcinoma (MCC), an aggressive form of ...
AJMC.com Managed Markets Network - Wed, 07 Oct 2015 08:22
|FDA grants avelumab fast track designation for metastatic Merkel cell carcinoma|
Healio - Wed, 07 Oct 2015 07:48
|Pfizer (PFE), Merck KGaA Announce Receipt of FDA Fast-Track Designation for ...|
StreetInsider.com - Wed, 07 Oct 2015 04:03
|Pfizer drug gets fast-track status|
theday.com - Wed, 07 Oct 2015 08:45
|Merck KGaA, Pfizer Announce Fast Track Designation For Avelumab|
Nasdaq - Wed, 07 Oct 2015 03:52
|Merck KGaA and Pfizer get their fifth-place immunotherapy on the FDA fast track|
FierceBiotech - Wed, 07 Oct 2015 08:00
|Merck and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA ...|
Business Wire India (press release) - Wed, 07 Oct 2015 05:22
|Bristol-Myers Squibb's Opdivo (nivolumab) Demonstrates Superior Renal Cell ...|
Bristol-Myers Squibb Company announced results from CheckMate -025, a Phase 3 clinical study comparing BMS's drug Opdivo (nivolumab) to everolimus in advanced renal cell carcinoma (RCC) after prior anti-angiogenic treatment. The CheckMate study ...
Immuno-Oncology News - Tue, 06 Oct 2015 05:00
|Ascend Announces Patients with Nodular Basal Cell Carcinoma Receives First ...|
MELBOURNE, Australia, Oct. 7, 2015 /PRNewswire/ -- Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company focused on developing innovative cancer therapeutics, today announced the first nodular Basal Cell Carcinoma patient (nBCC) ...
PR Newswire (press release) - Wed, 07 Oct 2015 06:07
|Global Patterns of Hepatocellular Carcinoma Management|
Background & Aims: Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort study undertaken to improve understanding of real-life ...
Medscape - Thu, 01 Oct 2015 21:18
|Drugs Show New Promise in Fighting Advanced Renal Cell Carcinoma|
Renal cell carcinoma, the most common form of the disease, is often diagnosed when it has already spread to other organs — and until recently, patients had few therapeutic options. Now, two studies from MSK researchers and colleagues point to ...
Memorial Sloan Kettering Cancer Center (blog) - Mon, 28 Sep 2015 06:23
|Cabozantinib Extends PFS More Than Everolimus in Renal Cell Carcinoma|
Cancer Therapy Advisor - Mon, 28 Sep 2015 09:01
|Nivolumab 'likely to change the treatment' of advanced renal cell carcinoma|
Healio - Sat, 26 Sep 2015 07:15
|Nivolumab Extends Survival in Advanced Renal Cell Carcinoma|
OncLive - Fri, 25 Sep 2015 15:18
|Positive Phase 3 Results for Opdivo in Renal Cell Carcinoma|
Monthly Prescribing Reference (registration) - Mon, 28 Sep 2015 12:41
|Immune checkpoint inhibitor increases survival in patients with advanced renal ...|
News-Medical.net - Fri, 25 Sep 2015 22:23
|Nivolumab Improves Overall Survival in Patients With Advanced Renal Cell Carcinoma|
Targeted Oncology - Mon, 28 Sep 2015 11:56
|Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ|
1. In a prospective cohort study of over 1000 patients with lobular carcinoma-in-situ, the use of a chemopreventative agent was associated with a significantly reduced risk of invasive breast cancer. 2. Age of diagnosis and family history were not ...
2 Minute Medicine - Fri, 02 Oct 2015 22:03
|FDA grants orphan drug designation to avelumab for Merkel cell carcinoma|
“We continue to dedicate significant resources to accelerate our clinical trial program, with a goal of helping patients who are fighting rare and difficult-to-treat diseases, such as Merkel cell carcinoma,” Luciano Rossetti, MD, head of Global ...
Healio - Mon, 28 Sep 2015 12:52